According to recently released polling data from Gallup, nearly half of all Americans have tried marijuana at one point in their lives, an all time high since they began asking the question in 1969 when only 4% of Americans admitted to having tried the substance.
Additionally, 12% of survey respondents said they currently consume marijuana.
“With 29 U.S. states allowing medical marijuana use, and eight allowing recreational use, legal cannabis is taking hold in American society.
There may be obstacles to marijuana becoming fully “accepted” in the United States. Attorney General Sessions appears to be cracking down on marijuana use, and driving under the influence of pot continues to be a concern for many.
Despite legal hurdles, however, a record-high percentage of Americans say they have tried marijuana.
Smoking pot is still not as prevalent as cigarette smoking in the U.S., at 17%, but current marijuana usage is about as high as it has been.
If more states legalize the drug, regular usage — or at least experimenting with marijuana — could rise. Legality may confer a certain societal acceptance of the drug. Sessions’ hopes to prosecute state-level marijuana crimes may prove to be a hindrance, but it is unlikely this multibillion-dollar industry will be stopped anytime soon.”
Revenues from Colorado’s legal cannabis industry have surpassed over a half-billion dollars since retail sales began on January 1, 2014.
According to an analysis by VS Strategies, cannabis-related taxes and fees have yielded $506,143,635 in new state revenue over the past three and one-half years. (Local tax revenue was excluded from the analysis.) Much of the revenue raised has gone to fund school construction projects, school-drop out and substance abuse prevention programs, and grant funding.
The half-billion dollar total far exceeds initial projections. Tax revenue from legal cannabis sales in Oregon and Washington have also exceeded regulators’ initial expectations. In Nevada, where retail sales to adult became legal on July 1, retailers reported over 40,000 transactions in just the first weekend.
Yesterday, NORML moderated a Facebook Congressional Conversation on marijuana law reform with Representatives Earl Blumenauer, Tom Garrett, Beto O’Rourke, and Justin Amash.
We discussed a wide range of issues including the needless burden of the federal driver’s license suspension mandate, access to medical marijuana, racial injustice, and pending bipartisan legislation to remove cannabis from the Controlled Substances Act.
The ongoing enforcement of cannabis prohibition financially burdens taxpayers, encroaches upon civil liberties, engenders disrespect for the law, impedes legitimate scientific research into the plant’s medicinal properties, and disproportionately impacts communities of color. Only when lawmakers speak honestly about the effects of prohibition and the senseless burdens it imposes on our communities will we be able to win substantial reform.
“At a time when 29 states and the District of Columbia have made the decision to regulate the sale and use of marijuana, we should rethink how the federal government approaches this drug. Our current approach to marijuana prevents legitimate medical use, fills our prisons with nonviolent offenders and continues to fuel drug violence,” said Representative Beto O’Rourke in a statement promoting the event.
In our continued effort to educate the lawmakers and the public, events like this will be able to open the eyes of those who have willfully ignored the issue.
NORML chapters throughout the country are working to advance legalization in state legislatures and, with your support, National NORML will continue to up the pressure in Washington, DC.
Select pharmacies in Uruguay are now dispensing marijuana to adults, under regulations that went into effect today.
Sixteen pharmacies are presently licensed to engage in cannabis sales, and some 5,000 adults so far have registered with the state to purchase marijuana products — which are capped at a price of $1.30 per gram.
Sales to foreign tourists are not permitted under the law.
Federal officials initially approved legislation in 2013 lifting Uruguay’s criminal prohibition of the plant. Under the policy change, citizens may cultivate up to six plants per household, and engage in collective cultivation as part of membership clubs. Rules and regulations governing the distribution of marijuana for medical purposes are overseen by the Ministry of Public Health.
House Bill 640, which takes effect in 60 days, eliminates criminal penalties for the possession of up to 3/4 of an ounce of cannabis and/or up to five grams of hashish for those age 18 or older. Under the new law, first time offenders will receive a civil violation punishable by a $100 fine.
Presently, first-time marijuana possession is punishable by up to one year in prison, a potential $2,000 fine, and a criminal record.
“New Hampshire will soon join the chorus of states that recognize the baseline level of dignity for it’s citizens and tourists who choose to consume marijuana,” said Justin Strekal, NORML Political Director. “Soon, throughout New England, individuals will be able to freely travel without the threat of jail time for possession of marijuana.”
New Hampshire is the only New England state that presently treats minor possession offenses as a criminal offense.
Over the first six months of 2017, the American Automobile Association (aka AAA) has been spreading misinformation and propaganda in a lobbying effort to defeat marijuana legalization legislative efforts in Connecticut, Delaware, Maryland, and other states.
As reported by Leafly.com, AAA representatives have recently preyed upon unsubstantiated fears regarding the alleged “increased plague of drugged driving” and the claim that “more babies will be born high” on marijuana in their lobbying efforts against adult use regulatory reforms. The distortions do nothing to advance the public debate surrounding legalization, but they do tarnish the organization’s reputation.
According to federal data, auto accident fatalities have fallen significantly over the past two decades – during the same time that a majority of US states have legalized marijuana for either medical or social use. In 1996 when California became the first state to legalize medical marijuana, the US National Highway Traffic Safety Administration reported that there were an estimated 37,500 fatal car crashes on US roadways. This total fell to under 30,000 by 2014.
Further, a recently published study in the American Journal of Public Health reports that fatal traffic accident rates in legal marijuana states are no different than those in states where cannabis remains illegal. A separate study published last year in the same journal previously reported that the enactment of medical marijuana legalization laws is associated with a reduction in traffic fatalities compared to other states, particularly among younger drivers.
One would hope that AAA would be nonpartisan in this debate; that they would be the group to separate the facts from the myths so that politicians and law enforcement would be more likely to pursue evidence-based policies with regard to regulating marijuana in a manner that strengthens public safety. Instead they’re largely fear-mongering and further politicizing the issue — calling for the continued criminalization and arrest of millions of Americans who choose to use marijuana privately and responsibly. By doing so, they are arguing in favor of the failed criminal justice policies of the past and they are alienating the 60 percent of Americans who endorse the outright legalization of recreational cannabis by adults (Gallup, 2016).
There are areas of public policy where AAA is absolutely in agreement with reform advocates, including NORML. For instance, we both agree that driving under the influence of cannabis should be discouraged and legally prohibited, and that the detection of either THC or its metabolites in blood or urine is not indicative of psychomotor impairment and, therefore, should not be used a legal standard of criminal liability.
Our hope is that some day groups like NORML and AAA can work together to advocate for rational policies that work to keep our roadways safe from the threat of impaired drivers. Specifically, we recognize — as does AAA — that there is a need for greater tools and methods to more accurately determine whether or not someone is under the influence of cannabis, such as via the use and promotion of handheld performance technology.
Tell AAA that the days of ‘reefer madness’ are over. It’s time for a rational and evidence-based discussion regarding how best to regulate the use of marijuana by adults and how to keep our roads safe.
State-registered medical cannabis patients may sue a private employer for discrimination if they are fired for their off-the-job marijuana use, according to a first in the nation ruling issued today by the Massachusetts Supreme Judicial Court.
Opining for the court, Chief Justice Ralph Gants determined that it is “not facially unreasonable” for employers to make exceptions to their substance abuse policies in instances where employees are using cannabis at home to treat a debilitating condition. “The fact that the employee’s possession of medical marijuana is in violation of federal law does not make it per se unreasonable as an accommodation,” he wrote.
The defendant in the case was fired on her first day on the job for testing positive for carboxy-THC on a company drug test. The former employee possessed a doctor’s recommendation to use cannabis to treat symptoms of Crohn’s disease and irritable bowel syndrome. Qualified patients may legally obtain cannabis in Massachusetts under a 2012 voter-initiated law.
The unanimous verdict reverses a lower court decision and is contrary to rulings in California, Colorado, Oregon, and Washington. In each of those states, the supreme courts ruled that employees had no legal protections if they were fired without cause for their state-sanctioned use of medical cannabis.
“Patients should never have to choose between their heath and their job and for the first time, a court has acknowledged that they shouldn’t have to do so,” NORML Executive Director Erik Altieri said. “It is our hope that courts in other jurisdictions begin to apply this same rationale to patients as well as to all adults who are using cannabis responsibly off-the-job in compliance with the laws of their states.”
The case is Barbuto v. Advantage Sales and Marketing LLC.
Over half of all young people entered into drug treatment for marijuana are placed there by the criminal justice system and this percentage is increasing, according to data published online in the journal Substance Use & Misuse.
A team of researchers from Binghamton University in New York and the University of Iowa reviewed youth marijuana treatment admission data (TEDS-A) during the years 1995 to 2012.
Investigators reported that youth admissions for cannabis rose 65 percent during the study period – from 52,894 annual admissions in 1995 to 87,528 in 2012. Admissions rose most precipitously among Latinos (an increase of 256 percent since 1995) and African American youth (an increase of 86 percent). Criminal justice system referrals rose 70 percent during this same period, and now account for 54 percent of all substance abuse admissions by young people.
Among those in treatment, half exhibited little if any evidence of suffering from marijuana dependence. Specifically, 30 percent of all young people admitted into marijuana treatment since 2008 had no record of having consumed cannabis in the 30 days prior to their admittance. Another 20 percent of those entered into treatment had use cannabis three times or fewer in the month prior to their admission. Prior evaluations of TEDS data among adults have yielded similar results.
“Our findings indicate that the severity of drug use involved in those admissions has decreased,” authors concluded. “This study highlights the importance of identifying youth in actual need of treatment services.”
Since the late 1990s, both youth use of marijuana and the prevalence of so-called ‘cannabis use disorder’ by young people have declined significantly.
An abstract of the study, “Trends in youth marijuana treatment admissions: Increasing admissions contrasted with decreasing drug involvement,” is online here. My commentary about the data, “Blowing the lid off the marijuana treatment racket,” appears on Alternet.org here.
This Wednesday, July 12th, members of the Senate Appropriations Committee will convene to discuss the Military Construction, Veterans Affairs and Related Agencies Appropriations bill. This legislative debate provides lawmakers with the opportunity to expand much needed medical marijuana access to our nation’s veterans.
Presently, V.A. doctors in states where cannabis therapy is permitted are forbidden from providing the paperwork necessary to complete a medical cannabis recommendation, thus forcing military veterans to seek the advice of a private, out-of-network physician. This issue can be solved by the approval of the Veterans Access Amendment, which ends these cruel and unnecessary restrictions on V.A. doctors and their patients.
Last year, majorities in both the US House and Senate voted to include similar language as part of the Fiscal Year 2017 Military Construction, Veterans Affairs and Related Agencies Appropriations bill. However, Republicans sitting on the House Appropriations Committee elected to remove the language from the bill during a concurrence vote. We must not allow a similar outcome again this year.
Veterans are increasingly turning to medical cannabis as an effective alternative to opioids and other conventional medications to treat conditions like chronic pain and post-traumatic stress. A retrospective review of patients’ symptoms published in 2014 in the Journal of Psychoactive Drugs reported a greater than 75 percent reduction on a scale of post-traumatic symptom scores following cannabis therapy. This is why, in recent months, two of the largest veterans’ rights groups — AMVETS and the American Legion — have resolved in favor of patients’ access to cannabis therapy.
Our veterans deserve the option to legally access a botanical product that is objectively safer than the litany of pharmaceutical drugs it could replace.
Thanks for all you do,
The NORML Team
P.S. Have you gotten your ticket for the 2017 NORML D.C. Conference and Lobby yet? Click here to register and come to Washington, DC September 10th-12th.
Study: No Increase In Problematic Cannabis Use By Young People Following Changes In Marijuana’s Legal Status
Writing in the Journal of Clinical Psychiatry, federal investigators from the US National Institute on Drug Abuse and the Substance Abuse Mental Health Services Administration evaluated marijuana use rates among young people (ages 12 to 17) between the years 2002 and 2014.
Researchers reported that the prevalence of past-year cannabis use by youth fell 17 percent during this time period. The prevalence of problematic use by young people fell by 25 percent – with a downward trend starting in 2011.
“In the United States, compared to 2002, even after adjusting for covariates, cannabis use decreased among youth during 2005-2014, and cannabis use disorder declined among youth cannabis users during 2013-2014,” authors concluded.
The study’s findings are consistent with those of numerous other papers reporting no uptick in youth marijuana use or abuse following the enactment of marijuana regulation, including those here, here, here, here, here, here, and here.
An abstract of the study, “Cannabis use and cannabis use disorders in the United States, 2002-2014,” appears online here.
Alcohol consumption is associated with negative changes in gray matter volume and in white matter integrity, while cannabis use is not, according to data published online ahead of print in the journal Addiction.
Investigators from the University of Colorado, Boulder and the Oregon Health & Science University evaluated neuroimaging data among adults (ages 18 to 55) and adolescents (ages 14 to 18). Authors identified an association between alcohol use and negative changes in brain structure, but identified no such association with cannabis.
“Alcohol use severity is associated with widespread lower gray matter volume and white matter integrity in adults, and with lower gray matter volume in adolescents,” they concluded. By contrast, “No associations were observed between structural measures and past 30-day cannabis use in adults or adolescents.”
Researchers acknowledged that their findings were similar to those of prior studies “suggesting that regionally specific differences between cannabis users and non-users are often inconsistent across studies and that some of the observed associations may actually be related to comorbid alcohol use.”
A 2015 brain imaging study published in The Journal of Neuroscience similarly reported that cannabis use was not positively associated with adverse changes in the brain, but that alcohol “has been unequivocally associated with deleterious effects on brain morphology and cognition in both adults and adolescents.”
Longitudinal data published in June in the British Medical Journal reported, “Alcohol consumption, even at moderate levels, is associated with adverse brain outcomes including hippocampal atrophy.”
An abstract of the study, “Structural Neuroimaging Correlates of Alcohol and Cannabis Use in Adolescents and Adults,” appears online here.
The US Drug Enforcement Administration has publicly reiterated its position that cannabidiol, a non-psychotropic cannabinoid, is properly categorized under federal law as a schedule I controlled substance — meaning that, by definition, it possesses “a high potential for abuse,” “no currently accepted medical use in treatment in the United States,” and lacks “accepted safety … under medical supervision.”
The agency has long contended that CBD, along with all organic cannabinoids, is — by default — a schedule I controlled substance because it is a naturally occurring component of the cannabis plant. (This position is similarly held by both the NIDA and the FDA.) Nonetheless, a growing body of science undermines the notion that CBD meets any of the criteria necessary for such classification.
Specifically, clinical trial data finds that CBD is “safe,” “non-toxic,” and “well tolerated” in human volunteers. Even the director of the US National Institute on Drug Abuse acknowledges that CBD is “not mind-altering” and that it “appears to be a safe drug with no addictive effects.”
Recently conducted controlled studies also acknowledge its therapeutic efficacy, particularly the ability of CBD dosing to mitigate treatment-resistant seizures, hypertension, and psychotic symptoms in humans. Other peer-reviewed data shows that CBD therapy holds promise for the treatment of “Parkinson’s disease, Alzheimer’s disease, cerebral ischemia, diabetes, rheumatoid arthritis, other inflammatory diseases, nausea and cancer.”
That is why in addition to the thirty states that presently recognize medical cannabis, an additional 16 states also explicitly recognize the use of CBD as a viable medical treatment.
Nonetheless, it remains unlikely that the DEA is going to amend its position any time soon. Further, police in recent months have begun initiating raids of CBD retailers, such as those reported here, here, and here. That is why it is critical that members of Congress move forward with legislation to remove the cannabis plant from the Controlled Substances Act.
Presently, several pieces of federal legislation are pending to amend the federal classification of CBD as a schedule I substance. These include:
HR 2020: Passage of this act would exclude CBD from the federal definition of ‘marihuana.’
S. 1374/HR 2920: Passage of these Acts would exempt from federal prosecution those who are engaged in state-sanctioned medical cannabis activities; it would also remove CBD from the federal definition of ‘marihuana.’
HR 2273/S. 1008: Passage of these Acts would exclude CBD and CBD-rich cannabis plants from the federal definition of ‘marihuana.’
You can contact your members of Congress in support of these bills and other pending legislation by visiting NORML’s Take Action Center here.
NORML’s 2017 Conference at the Capitol Hilton in Washington, DC and Congressional Lobby Day at the United States Capitol is scheduled for September 10th-12th. Hundreds of marijuana consumers, activists, patients and business owners are expected to attend a day-long training and informational conference on Monday and re-convene on The Hill Tuesday to personally lobby their elected members of the House of Representatives and Senate.
Whether you’re a longtime activist, college student, medical marijuana patient, or simply a NORML supporter, consider taking this all important step to directly lobby your members of Congress in support of common sense marijuana law reform. During your stay, you will meet and network with like minded activists from across the country, and your time on Capitol Hill will ensure that our message is brought face-to-face to those in Congress who need to hear it the most.
We will be lobbying for expanded protections for those states that have reformed their laws, and to protect the progress that we have made from Attorney General Jeff Sessions and his rogue Justice Department. Time and time again, AG Sessions has made it clear that he thinks those of us who consume cannabis are “not good people.” We will be in the halls of Congress to set the record straight.
The DMV NORML Social, benefiting DC, Virginia, and Maryland Chapters of NORML, will be held on Sunday, September 10, at The Dew Drop Inn, located at 2801 8th St NE, Washington, DC 20017 — a five minute walk from the Brookland-CUA Redline Metro Stop.
The Conference portion of the event will be held Monday, September 11th at the Capitol Hilton which is located at 1001 16th St NW. It is walking distance from the Farragut West, Farragut North, and McPherson Square Metro Stations, and the Hilton is easily accessible from the Red, Blue, Orange, or Silver Metro Lines.
The NORML Monday Night Party location details will be given to registered attendees in the weeks leading up to the event.
See you in September,
The NORML Team
Representatives of Florida for Care filed litigation today challenging a statewide ban on medical cannabis smoking. The suit was expected after lawmakers approved legislation (SB 8A) in June amending Amendment 2 — a voter initiated constitutional amendment permitting the use and distribution of medical cannabis. Seventy-one percent of voters approved the amendment in November.
Senate Bill 8A amends the definition of medical cannabis in a manner that prohibits “marijuana in a form for smoking” and that bars the personal possession of herbal cannabis flowers, except in instances where they are contained “in a sealed, tamper-proof receptacle for vaping.” The Florida for Care suit argues that these changes inconsistent with the constitutional definition of marijuana, as passed by voters, and therefore should not be implemented.
The lawsuit argues, “Inhalation is a medically effective and efficient way to deliver tetrahydrocannabinol (THC), and other cannabinoids, to the bloodstream. … By redefining the constitutionally defined term ‘medical use’ to exclude smoking, the Legislature substitutes its medical judgment for that of ‘a licensed Florida physician’ and is in direct conflict with the specifically articulated Constitutional process.”
Under the revised law, patients diagnosed with cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn’s disease, Parkinson’s disease, or multiple sclerosis — or who suffer from chronic pain related to any of these diseases — are eligible to receive a 70-day supply of cannabis-infused oils or edible products from a limited number of state-licensed dispensing facilities.
NORML has long argued against regulations that limit or prohibit patients’ access to whole-plant cannabis in lieu of cannabis-derived extracts or pills. Cannabis inhalation is not associated with increased instances of lung cancer, COPD, or other tobacco-related adverse effects on pulmonary function. Inhaled cannabis is fast acting and permits patients to accurately self-regulate their dose. By contrast, non-herbal forms of cannabis possess delayed onset and their effects can often be far less predictable than those of herbal cannabis. Many patients seeking rapid relief of symptoms do not benefit from pills, tinctures, or edibles, and such restrictions unnecessarily limit patients’ choices.
If the court invalidates SB 8A, the task of writing the rules for implementing the initiative — which must be operational by October — will fall to the Florida Department of Health.
A common cliché for overcoming a difficult obstacle asks, “how do you eat an elephant?” The answer is, “one bite at a time.” In Virginia politics, the tough question facing cannabis policy reform advocates is, “how do you change the minds of political Elephants?” The answer is, “one law at a time.” Although progress in cannabis reform has been slow in Virginia, two recent bills signed by Governor Terry McAuliffe are significant signs that change is coming, and quicker than ever before.Ending Automatic Driver’s License Suspension for Cannabis Possession
In May 2017, Gov. McAuliffe had a signing ceremony for Senator Adam Ebbin’s Senate bill 784 and Delegate Les Adams’ House bill 2051. These companion bills ended the absolute requirement that Virginians convicted of marijuana possession lose their driver’s license. Until this change, which takes effect July 1, the judge had no option but to suspend, even if the offense was totally unrelated to a vehicle. A driver’s license is necessary in commuter-based economies such as Virginia, where most residents work, attend school, receive medical treatment, or worship outside of their home city, and the public transportation is less then reliable.
Virginia NORML led the lobbying for this bill, and helped sway lawmakers in the General Assembly who were wary of the proposed changes. The legislators were convinced by explaining the law in detail, and highlighting the positive results from allowing individuals to maintain their license for work and education – no extreme rhetoric or exaggeration needed. Ryan Johnson, membership coordinator for Virginia NORML, testified for both pieces of legislation was congratulated by many thankful legislators at the ceremony.
Gov. Terry McAuliffe (VA-D) and Ryan Johnson
Ryan Johnson with Delegate Les Adams (R-16)
“With Virginia NORML’s guidance, I was able to craft impactful testimony, helping pass meaningful legislation that will make a difference for thousands of Virginians,” said Ryan Johnson at Gov. McAuliffe’s ceremony. “I was humbled by how many legislators thanked me for stepping outside of my comfort zone and sharing my story in the 2017 General Assembly.”
Del. Paul Krizek (D-44), Del. Les Adams (R-16) ,Sen. Scott Surovell (D-36), Del. Alfonso Lopez (D-49), Ryan Johnson, Sen. Adam Ebbin (D-30)Watch the video
The new law is a significant step for cannabis policy reform in Virginia for two reasons. First, this is one of the very few marijuana-related criminal justice reforms that advocates have successfully pushed through the difficult, Republican-controlled House subcommittees. Those subcommittees are the sticking point for most criminal justice reform legislation, the bottle neck that prevents bills from proceeding to a full House vote. Second, this is important because it allows judges discretion to apply the standard first-offender’s program and community service to an adult discovered possessing cannabis somewhere completely removed from any vehicles. Admittedly, this is a small step. However, every step, even the very small ones, put Virginia closer to a more sensible criminal justice system that does not criminalize marijuana possession or consumption.Welcome to the Medical Cannabis States Club, Virginia
In June 2017, Gov. McAuliffe had another bill signing ceremony, this one for Senator Marsden’s Senate bill 1027. This bill is significant because it officially makes Virginia a medical cannabis state. Medical cannabis dispensaries will be called “pharmaceutical processors,” and will become medical cannabis patients’ legal source of the cannabis oil permitted under Virginia law. The processors will be vertically integrated facilities. That means the plants will be grown, cured, and trimmed onsite; all extraction, distillation, and synthesis of custom biopharmaceutical medicines will be done in the on-site laboratory; and, finally, patients will interact with and receive medication from a pharmacist. Unlike the medical cannabis dispensaries in Colorado, this will more closely resemble a traditional pharmacy.
Virginia families were instrumental in getting this landmark legislation passed. However, despite the great success, the law has serious shortcomings. There will only be five (5) pharmaceutical processors. This places a huge burden on applicants, financially and logistically, and could result in the exclusion of start-up ventures owned by minorities, women, and veterans without access to large capital resources. Second, the related laws allowing patient access to medical cannabis is very short: one (1). Only one patient group, those with intractable epilepsy, can possess medical cannabis oil. The major legislative goal for the 2018 session is the “Let Doctors Decide” bill, which would end the eugenics-style creation of state-permitted patient groups and instead allow trained medical professionals to decide if cannabis would be effective for the individual patient’s treatment plan. Jenn Michelle Pedini was at the ceremony representing Virginia NORML, and spoke to the families of several epilepsy patients and lawmakers who had supported the bill.
Sen. Dave Marsden (D-37) and many families watch as Gov. McAuliffe signs historic medical cannabis legislation. Photo courtesy Michaele White, Governor’s Office.
“It was an exciting day for the families who spent hours at the General Assembly gaining support for this bill which passed unanimously in both the House and Senate. We are looking forward to continuing this path next year and expanding the current law to include all patients for whom medical cannabis would provide relief,” said Beth Collins, Senior Director Government Relations and External Affairs at Americans for Safe Access, and mother of a child with intractable epilepsy.
These landmark bills are significant signs of the change coming in Virginia’s cannabis policy. Decriminalization is being studied by the State Crime Commission, following a request by Senate Majority leader Tommy Norment. The Driver’s License bill may be the first overly punitive prohibition measure to fall, and like dominoes, the changes to criminal justice reform will gain momentum and culminate in decriminalization of adult cannabis possession within the next couple years. The pharmaceutical processor bill is a huge hurdle for both patients seeking legal access to medical cannabis medications, and for individuals interested in the regulated cannabis industry. Although Virginia’s cannabis industry will fall under heavy regulation and oversight by the Commonwealth, the new industry presents new opportunities, jobs, and tax revenue.
Virginia NORML is the leading cannabis law reform organization in Virginia, but we can only continue our success in changing outdated laws with your help! The Summer of Change Campaign is currently underway, and we are trying to raise $42,000 to support our efforts in the 2018 session and the push for “Let Doctors Decide.” Virginia has a major election this year, and the outcome could determine the success – or failure – of our efforts. Donate today to the Summer of Change campaign! With your help, Virginia NORML will continue its track record of success in Richmond bringing marijuana policy reform.
The closure of medical marijuana dispensaries is associated with an increase in larceny, property crimes, and other criminal activities, according to data published in the Journal of Urban Economics.
Researchers at the University of Southern California and the University of California, Irvine assessed the impact of dispensary closures on neighborhood crimes rates in the city of Los Angeles. Investigators analyzed crime data in the days immediately prior to and then immediately after the city ordered several hundred operators to be closed. Authors reported an immediate increase in criminal activity – particularly property crime, larceny, and auto break ins – in the areas where dispensary operations were forced to close as compared to those neighborhoods were dispensaries remained open.
“[W]e find no evidence that closures decreased crime,” authors wrote. “Instead, we find a significant relative increase in crime around closed dispensaries.” Specifically, researchers estimated that “an open dispensary provides over $30,000 per year in social benefit in terms of larcenies prevented.”
They concluded, “Contrary to popular wisdom, we find an immediate increase in crime around dispensaries ordered to close relative to those allowed to remain open. The increase is specific to the type of crime most plausibly deterred by bystanders, and is correlated with neighborhood walkability. … A likely … mechanism is that ‘eyes upon the street’ deter some types of crime.”
The findings are consistent with those of prior studies determining that dispensary operations are not associated with ‘spillover effects’ in local communities, such as increased teen use or increased criminality.
An abstract of the study, “Going to pot? The impact of dispensary closures on crime,” appears online here.
The prolonged daily administration of cannabinoids is associated with a reduction in migraine headache frequency, according to clinical trial data presented at the 3rd Congress of the European Academy of Neurology.
Italian researchers compared the efficacy of oral cannabinoid treatments versus amitriptyline – an anti-depressant commonly prescribed for migraines – in 79 chronic migraine patients over a period of three months. Subjects treated daily with a 200mg dose of a combination of THC and CBD achieved a 40 percent reduction in migraine frequency – a result that was similar to the efficacy of amitriptyline therapy.
Subjects also reported that cannabinoid therapy significantly reduced acute migraine pain, but only when taken at doses above 100mg. Oral cannabinoid treatment was less effective among patients suffering from cluster headaches.
“We were able to demonstrate that cannabinoids are an alternative to established treatments in migraine prevention,” researchers concluded.
Some five million Americans are estimated to experience at least one migraine attack per month, and the condition is the 19th leading cause of disability worldwide.
According to retrospective data published last year in the journal Pharmacotherapy, medical cannabis consumption is often associated with a significant decrease in migraine frequency, and may even abort migraine onset in some patients.
A just published review of several studies and case-reports specific to the use of cannabis and cannabinoids in the journal Cannabis and Cannabinoid Research concludes: “[I]t appears likely that cannabis will emerge as a potential treatment for some headache sufferers.”
An abstract of the study, “Cannabinoids suitable for migraine prevention,” appears online here.
What are your plans this Fourth of July weekend? If you are like most Americans, you are likely to be having a cookout, watching fireworks with friends and family, or engaging in some other social event that celebrates your freedom.
But for the millions of Americans who consume cannabis, freedom can be fleeting.
In many states, our fellow citizens still face the possibility of arrest, criminal prosecution, and jail time for a first offense marijuana possession charge. For instance, in Arizona and Florida, first-time possession offenders may face felony charges. In Oklahoma, growing even a single plant is punishable by up to life in prison.
At NORML we understand that this harsh reality is probably not something that you think about every single day — particularly on July 4th. But we do. That is why we are working hard to empower our national network of engaged citizens — citizens like you — to change America’s antiquated and punitive marijuana laws. And, because of you and your efforts, we are succeeding!
It is the highest ideal of American democracy that our nation has a well-informed and politically engaged electorate. That is why every week — via our blog, social networks, and weekly e-zine — NORML aims to arm our supporters with the latest science and news, as well as legislative and legal developments pertaining to cannabis and cannabis policy. Via the NORML Action Center at www.norml.org/act, we keep you up to date on and engaged in all ongoing state and federal legislative efforts to reform marijuana prohibition and restore our freedoms. And we thank the 100,000+ individuals that have taken action over the past few months.
Now, more than ever, it is crucial that we come together and assert our authority over our elected officials. The Declaration of Independence explicitly states: That to secure these rights, Governments are instituted among Men, deriving their just powers from the consent of the governed.
In sum: it’s our responsibility to compel our elected officials to institute change.
Our system of government is not perfect. In fact, it is far from it. But for hundreds of years, citizens have organized and struggled to come closer to Thomas Jefferson’s iconic aspiration, “That all men are created equal; that they are endowed by their Creator with certain unalienable Rights; that among these are Life, Liberty and the pursuit of Happiness.”
Thomas Jefferson legally grew cannabis. You should be able to as well.
Happy Fourth of July,
The NORML Team
One of NORML’s primary missions is to move public opinion sufficiently to legalize the responsible use of marijuana by adults. One of the ways we successfully achieve this goal is by debunking marijuana myths and half-truths via the publication of timely op-eds in online and print media. Since the mainstream media seldom casts a critical eye toward many of the more over-the-top claims about cannabis, we take it upon ourselves to set the record straight.
The majority of NORML’s rebuttals are penned by Deputy Director Paul Armentano. In the past few weeks, he has published numerous op-eds rebuking a litany of popular, but altogether specious claims about the cannabis plant.
Below are links to a sampling of his recent columns.:
“Cannabis mitigates opioid abuse — the science says so”
in Santa Fe New Mexican
“The Deputy Attorney General is ignorant to the science of medical marijuana”
in The Daily Caller
For a broader sampling of NORML-centric columns and media hits, please visit NORML’s ‘In the Media’ archive here.
If you see the importance of NORML’s educational and media outreach efforts, please feel free to show your support by making a contribution here.
At the federal level, the House Appropriations Committee this week released its 2018 Commerce, Justice, Science (CJS) Appropriations bill, which determines the funding levels for numerous federal agencies, including the Department of Justice. Predictably, the bill does not include language — known as the Rohrabacher-Blumenauer amendment — limiting the Justice Department from taking action against state-sanctioned medical cannabis producers, retailers, or consumers.
The text of this amendment has never been included in the base bill of the CJS Appropriations bill. In every case of its passage, lawmakers have needed to add the language as a separate rider to the legislation and then vote on it on the floor of the House.
This year is no exception. Our allies in Congress anticipate a similar process to take place this fall and they are confident that we will once again be victorious — despite the best efforts of our opponents.
At the state level, the biggest development has been the introduction of Wisconsin Senate Bill 318, to amend state law so that marijuana possession offenses (up to 10 grams) are reduced to a civil offense, punishable by a fine of $100, and no longer have the threat of jail time.
As we prepare for the Fourth of July celebration, it’s always good to have some critical self-reflection about how our democracy is functioning. Our system of government is not perfect – in fact, it is far from it. But for hundreds of years, citizens have organized and struggled to come closer to Thomas Jefferson’s iconic aspiration, “That all men are created equal; that they are endowed by their Creator with certain unalienable Rights; that among these are Life, Liberty and the pursuit of Happiness.”
Thomas Jefferson legally grew cannabis. You should be able to as well.
Following are the bills from around the country that we’ve tracked this week and as always, check http://norml.org/act for legislation pending in your state.
Don’t forget to sign up for our email list and we will keep you posted as these bills and more move through your home state legislature and at the federal level.
Thanks for all you do and keep fighting,
Protect Lawful Medical Marijuana Programs: The House Appropriations Committee released its 2018 Commerce, Justice, Science (CJS) Appropriations bill, which determines the funding levels for numerous federal agencies, including the Department of Justice. Predictably, the bill does not include language — known as the Rohrabacher-Blumenauer amendment — limiting the Justice Department from taking action against state-sanctioned medical cannabis producers, retailers, or consumers.
Join The Caucus: With public support for reforming marijuana laws at an all time high, Reps. Earl Blumenauer (D-OR), Dana Rohrabacher (R-CA), Jared Polis (D-CO), and Don Young (R-AK) earlier this year formed the Congressional Cannabis Caucus to develop and promote sensible cannabis policy reform and work to ease the tension between federal and state cannabis laws.
Legislation is pending, Assembly Bill 1578, to try and limit potential federal interference in the state’s marijuana regulatory laws.
The bill states, “This bill would prohibit a state or local agency, as defined, from taking certain actions without a court order signed by a judge, including using agency money, facilities, property, equipment, or personnel to assist a federal agency to investigate, detain, detect, report, or arrest a person for commercial or noncommercial marijuana or medical cannabis activity that is authorized by law in the State of California and transferring an individual to federal law enforcement authorities for purposes of marijuana enforcement.”
Update: AB-1578 was passed by members of the Senate Public Safety Committee on June 27 by a 5-2 vote.
Senate Bill 24, introduced by Senate Majority Leader Margaret Rose Henry to expand the list of qualifying conditions to medical marijuana to include PTSD.
On June 22 Senate Bill 24 was passed the Health & Human Development Committee in statehouse.
Senate Bill 318 has been introduced to amend state law so that marijuana possession offenses (up to 10 grams) are reduced to a civil offense, punishable by a fine of $100.
The policy proposed by this bill is line with those of numerous other states, including Nebraska and Ohio. Such a change will save taxpayers money and allow police and the courts to re-prioritize their resources toward addressing more serious crimes.